Search results
Showing 16 to 30 of 126 results for thyroid* OR hypothyroid* OR Hyperthyroid* OR goiter
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.
Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development [GID-TA11160] Expected publication date: TBC
Awaiting development [GID-TA11398] Expected publication date: 13 November 2024
In development [GID-TA11047] Expected publication date: 21 August 2024
This indicator covers the contractor establishing and maintaining a register of patients with hypothyroidism who are currently treated with levothyroxine. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM99.
This indicator covers the proportion of children and young people with type 1 diabetes who have been screened for thyroid disease in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG75
This indicator covers the percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 6 months before or after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM09
This indicator covers the percentage of patients on the learning disability register with Down's Syndrome aged 18 and over who have a record of blood TSH in the previous 15 months (excluding those who are on the thyroid disease register). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM04
This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72
effectiveness of dosimetry-guided radioactive iodine strategies for hyperthyroidism? Any explanatory notes(if applicable) Why the...
What is the clinical and cost effectiveness of iodine for people with subclinical hypothyroidism?
subclinical hypothyroidism? Any explanatory notes(if applicable) Source guidance details Comes from guidance Thyroid...
What is the clinical and cost effectiveness of selenium for people with subclinical hypothyroidism?
subclinical hypothyroidism? Any explanatory notes(if applicable) Source guidance details Comes from guidance Thyroid...
subclinical hypothyroidism? Any explanatory notes(if applicable) Source guidance details Comes from guidance Thyroid...